In vitro evaluation of hydroxyapatite, β-tricalcium phosphate, graphene oxide and zinc oxide for osteochondral regeneration under inflammatory conditions Authors: Roman Novotný, Izabella Rajzer, Jana Franková Published: 2026 ABSTRACT AbstractThe repair of osteochondral defects is challenging due to differing regenerative capacities of bone and cartilage, a challenge that is often exacerbated by chronic inflammation. This study evaluated the immunomodulatory and regenerative potential of hydroxyapatite (HAp), β-tricalcium phosphate (β-TCP), graphene oxide (GO), and zinc oxide (ZnO) on osteoblast-like cells (Saos-2) and chondrocyte-like cells (SW1353) under IL-1β-induced inflammatory conditions. An MTT assay was used to measure cell viability at different concentrations of substances. To investigate the ability of Saos-2 cells to synthesize an inorganic extracellular matrix (ECM), mineralisation was observed via Alizarin Red staining and alkaline phosphatase (ALP) activity. The protein production of pro-COL1, pro-COL2, ACAN, MMP-9, IL-6, IL-8, BMP-2/4, RUNX2, and SOX9 was assessed using ELISA and Western blotting. The gene expression of RUNX2, SOX9, MMP-3, ADAMTS-5, COL10A1, ACAN, BGLAP, and FGF-2 was evaluated using RT-qPCR. Under inflammatory conditions, all the evaluated substances maintained basal matrix synthesis while suppressing the expression of ECM-degrading enzymes. Notably, GO exhibited a strong chondroprotective effect in SW1353 cells by significantly downregulating the expression of RUNX2 and FGF-2. Conversely, ZnO was found to impair mineralisation via the cytoplasmic trapping of RUNX2. Furthermore, their distinct impact on cellular phenotypes, ranging from GO-mediated chondroprotection to the inhibition of mineralisation by ZnO, highlights that the strategic, layer-specific integration of these substances is essential for actively guiding and sustaining the complex process of osteochondral healing. Consequently, our findings demonstrate a dual therapeutic benefit, in which the evaluated substances simultaneously suppress ECM degradation and support fundamental matrix synthesis under inflammatory stress.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11010-026-05728-2.Keywords: Osteochondral regeneration, Bioactive compounds, Osteoblasts, Chondrocytes, Inflammation Introduction An osteochondral defect is a localised joint injury that damages both the articular cartilage and the underlying subchondral bone layer [1]. If the injury is not treated, irreversible changes in tissue integrity may occur [2]. This often leads to chronic pain, mechanical locking, and the premature, irreversible onset of degenerative osteoarthritis [3]. Because bone and cartilage have different physical properties and healing capacities, treating these defects is medically challenging [4]. Clinically, these defects are frequently accompanied by a persistent inflammatory microenvironment, predominantly mediated by elevated levels of pro-inflammatory cytokines, most notably interleukin-1β (IL-1β) [5]. The presence of IL-1β triggers a localized cytokine cascade that profoundly alters the metabolic state of both osteochondral progenitors and mature cells [6]. Specifically, this cascade drives a robust increase in the activity of matrix metalloproteinases (MMPs), which degrades the extracellular matrix (ECM) [6]. This amplified response not only impairs healing at the defect site but also severely damages the structural and functional integrity of the surrounding, healthy tissue [7]. Consequently, the fundamental ECM homeostasis required for bone and cartilage maintenance is disrupted [8]. Therefore, there is a critical need for materials with bioactive additives that can actively counteract this inflammatory degradation and support tissue repair under these challenging conditions. Surgical fixation is restricted to acute injuries with viable fragments, and mosaicplasty is limited by donor-site morbidity and graft availability. Tissue engineering represents a promising, scalable alternative capable of overcoming these conventional drawbacks. Materials used in tissue engineering typically serve as three-dimensional scaffolds designed to structurally mimic the native ECM [1, 9–11]. Furthermore, modern biomaterial design has evolved from providing merely passive structural templates to creating bioactive systems in which various additives such as HAp, β-TCP, GO, and ZnO actively participate in tissue remodelling [1, 12–14]. To address this, various bioactive substances are being explored [1, 11, 15]. Inorganic matrices are critical in bone tissue, with substances such as HAp and β-TCP serving as recognized osteoconductive agents with similarity to the native bone mineral phase [1, 11, 16]. While the role of HAp and β-TCP as additives in scaffolds is well-established, their specific immunomodulatory behaviour under a chronic inflammatory environment (e.g. IL-1β rich) is less defined. However, recent studies suggest HAp can induce the polarisation of macrophages towards the M2 phenotype [17, 18], HAp and β-TCP can support basal mineralisation under inflammatory condition [19, 20]. Separately, GO and ZnO were chosen for their known ability to structurally reinforce hydrogels or provide vital antimicrobial protection [21–23]. Beyond mechanical reinforcement, GO has demonstrated potent ROS scavenging capabilities and TGF-β pathway activation that protect cells against inflammatory degradation of ECM [24, 25]. ZnO exhibits ion release that can modulate local cytokine expression and counteract inflammatory cytotoxicity, despite potential concentration-dependent impacts on osteogenic pathways [16]. These properties provide a promising strategy to actively counteract inflammatory degradation and stimulate cell differentiation. Understanding how these distinct classes of substances interact with bone-like and cartilage-like cells under inflammatory conditions could provide a broader understanding of their capabilities in osteochondral defect regeneration [25, 26]. As current literature only evaluates these four substances under non-inflammatory conditions, this study’s novel contribution is its systematic comparison of HAp, β-TCP, GO and ZnO under IL-1β-stimulated inflammatory conditions. This setup enables us to distinguish baseline biocompatibility from active immunomodulatory effects, ranging from cellular protection to the preservation of regenerative capacity, by testing each substance on Saos-2 and SW1353 cell lines. We hypothesized that the application of bioactive substances (HAp, β-TCP, GO, and ZnO) under IL-1β-induced inflammatory stress would significantly counteract extracellular matrix (ECM) degradation and support basal matrix synthesis in both osteoblast-like and chondrocyte-like cells (Fig. 1). The aim of the study was to evaluate the immunomodulatory and regenerative capacity of HAp, β-TCP, GO, and ZnO on Saos-2 and SW1353 cells under an IL-1β-simulated inflammatory microenvironment. Viability, ALP activity, mineralisation, protein production of pro-COL1, pro-COL2, ACAN, MMP-9, IL-6, IL-8, BMP-2/4, RUNX2, and SOX9, gene expression of RUNX2, SOX9, MMP-3, ADAMTS-5, COL10A1, ACAN, BGLAP, and FGF-2, together with RUNX2 distribution in cells, were evaluated using MTT assays, Alizarin Red staining, ELISA, Western blot, RT-qPCR, and fluorescence microscopy. Study hypothesis. Pathophysiological impact of inflammatory stress on an osteochondral defect, leading to increased ECM degradation, reduced ECM synthesis, and impaired homeostasis. The application of substances (HAp, β-TCP, GO, and ZnO) aims to counteract these effects Materials and methods The tested substances Hydroxyapatite (HAp; 99.8% trace metals basis, excluding Mg), β-tricalcium phosphate (β-TCP), graphene oxide (GO), and zinc oxide (ZnO) were purchased from Merck (Germany) and used as received. HAp (Ca₁₀(PO₄)₆(OH)₂) and β-TCP (Ca₃(PO₄)₂) served as calcium phosphate-based components. GO was supplied as a powder comprising 15–20 layers with 4–10% edge oxidation. According to the manufacturer’s specifications, ZnO was provided as a nanopowder with a particle size of < 50 nm. The exact primary particle sizes for the HAp, -TCP, and GO powders were not specified by the manufacturer. Cell lines and cultivation The Saos-2 cell line was purchased from ECACC (European Collection of Authenticated Cell Cultures, United Kingdom), and the SW1353 cell line was obtained from ATCC (American Type Culture Collections, USA). The Saos-2 cells were cultured in McCoyʹs 5 A medium (Merck), and SW1353 cells in DMEM medium (SERANA, Germany). Both media were supplemented with 10% fetal bovine serum (FBS, SERANA) and penicillin-streptomycin (10,000 U penicillin, 10 mg streptomycin/ml, Merck). Cells were cultured at 37 °C in 5% CO2. Upon reaching 80% confluence, cells were subcultured. The culture medium was removed, cells were washed with PBS, and trypsin-EDTA (0.25 wt%, Thermo Fisher Scientific, USA) was added. Flasks were incubated at 37 ˚C, 5% CO2 for 3 min until the cells detached. After detachment, the culture medium with serum was added. The cell suspension was centrifuged at 1,000 RPM for 3 min at room temperature. After centrifugation, the supernatant was discarded, and the cell pellet was resuspended in fresh medium with FBS. Cells were then transferred to new flasks, Petri dishes or well plates. Application of the tested substances The studied substances were irradiated by UV light. The stock dispersion (2 mg/ml) was prepared in 1 ml serum free medium containing 10% (v/v) DMSO (Carl ROTH, Germany). Prior to use, the stock dispersion was thoroughly vortexed for 2 min to ensure a homogenous distribution and minimize powder agglomeration. Aliquots of the stock dispersion were then diluted using serum-free culture medium to achieve final working concentrations 1, 0.5, 0.25, and 0.125 µg/ml for the MTT assay. Due to the high dilution factor, in 1 µg/ml substance dispersion was the final concentration of DMSO 0.005% (v/v). The concentration 0.5 µg/ml (serum with FBS or serum-free medium) was used for other biological assays. The term subtoxic is defined here as the highest uniform dose that maintained cell viability above the 70% threshold established by the ISO 10993-5 guidelines for in vitro cytotoxicity [27]. This subtoxic concentration was explicitly chosen over the lower concentrations (0.125 and 0.25 µg/ml) to maximize the bioactive dose necessary to effectively counteract the severe IL-1β-induced inflammatory stress. MTT assay Cells were seeded into 96-well plates at a concentration of cells/ml (200 µl/well) and incubated at 37 °C, 5% CO2 for 24 h. Substances were dissolved in DMSO and diluted in serum-free medium at concentrations of 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml and 0.125 µg/ml. Wells were then aspirated and washed with PBS. The substance solutions were then added to the wells (200 µl). Control wells had cells with only serum-free medium. Cells were incubated for 24 h at 37 ˚C, 5% CO2. After the incubation period, the medium was removed and the MTT solution (Merck) was added (1:10, MTT in medium without FBS). After the incubation period, the MTT solution was removed, and DMSO (Carl ROTH) with NH3 (Carl ROTH) was added (100:1). Absorbance was measured at 550 nm using Infinite M200 PRO (TECAN, Switzerland). IL-1β cell treatment When cells in Petri dishes reached 80% confluence, the FBS-containing medium was replaced with a serum-free medium containing IL-1β (Merck, 1 ng/ml) for 24 h to induce inflammation. After this, the IL-1β-containing medium was replaced with medium containing the dissolved substances (0.5 µg/ml). After 5–24 h of incubation, the medium was collected for ELISA experiments or discarded. Control cells were treated with or without IL-1β, without substances. The cells were seeded into 6-well plates at 0.25× cells/ml in 2 ml of medium. After 24 h, the FBS-containing medium was replaced with serum-free medium containing the substances (0.5 µg/ml). The cells with serum-free medium were used as the control. After 1 day or 1 week, the medium was discarded, and the wells were washed with PBS. Detection of alkaline phosphatase activity To measure ALP activity, FBS-containing medium was aspirated from 6-well plates, and a 0.2% Triton X-100 solution (Carl ROTH, diluted 1:10 in PBS) was added to cells. The lysed cells were scraped and transferred to tubes for three freeze-thaw cycles: 15 min at −80 °C followed by 15 min at 37 °C. Then, 25 µl of each lysate or standard was mixed with 25 µl PBS and 50 µl buffer solution in a 96-well plate. After 5 min of incubation at 37 °C, 50 µl of substrate was added. After a 15-minute incubation at 37 °C, the reaction was stopped by adding 50 µl of 1 M NaOH. Absorbance was measured at 405 nm using Infinite M200 PRO (TECAN). ALP activity was normalized to the total protein concentration determined by the Bradford method. ELISA method Experiments were done on cells which were in contact with the substances and IL-1β or treated with the substances without the additional inflammation step. Interleukin 6 (IL-6), Interleukin 8 (IL-8), matrix metalloproteinase-9 (MMP-9), pro-collagen type II (pro-COL2), and pro-collagen type I (pro-COL1) in the cell supernatant were examined using a Human ELISA Development Kit (Peprotech, USA (IL-6, IL-8); R&D Systems, USA (pro-COL2, MMP-9, pro-COL1)) according to the manufacturer’s instructions. Bradford assay The total protein content was measured by Bradford Assay. Briefly, 5 µl of lysate for the ALP assay and western blot method was diluted with 15 µl PBS in a 96-well plate. Bovine serum albumin (BSA, Carl ROTH) was used as the standard (0–1 mg/ml). Then, 200 µl of Bradford reagent was added to each well. After 30 s of mixing, absorbance was measured at 595 nm using Infinite M200 PRO (TECAN). Cell mineralisation and alizarin red test Saos-2 cells were seeded on Petri dishes and cultivated in 3 types of culture FBS-containing medium: mineralisation medium (MA: 50µM ascorbic acid, 10mM β-glycerolphosphate and 1µM dexamethasone), mineralisation medium with CaCl2 (MA + CaCl2 (5mM)), and mineralisation medium MA with the substances (0.5 µg/ml). Untreated cells were used as a control (C). The culture medium was changed every 3 days, and the cells were cultured for 3 weeks. After the cultured period, the cells were stained with alizarin red. The culture medium was removed, and cells were washed twice with PBS. Cells were fixed with cold formalin (10%; Merck) for 10 min. After washing the cells twice with PBS, cells were stained by adding sufficient alizarin red S staining solution (2%; Merck). After an incubation time of 15 min in the dark, the alizarin red S staining solution was removed, and the cell monolayer was washed 3 times with PBS. The staining was analysed under a fluorescence microscope (IX3-CBH, Olympus, Japan) and pictures were taken with an ORCA digital CMOS camera and evaluated with cellSens Dimension 4.3 (Olympus). Western blot For Western blotting, cells were scraped in PBS and centrifuged (3000 RPM, 5 min, 4 °C). The supernatant was discarded, and RIPA buffer containing PMSF (phenylmethylsulfonyl fluoride; Merck; 1:100) was added to the pellet, followed by vortexing. Lysates were incubated for 30 min, then centrifuged at 14,000 RPM for 15 min at 4 °C. The protein-containing supernatant was collected. Protein samples were mixed with loading buffer (1:1) and loaded onto 1.5 mm 8% polyacrylamide gels (25 µg per well). After SDS-PAGE, proteins were transferred to PVDF membranes using the Trans-Blot Turbo Transfer System. Membranes were blocked for 2 h and incubated overnight with primary antibodies (1:500) against SOX9, RUNX2, ACAN, and BMP-2/4 from Santa Cruz Biotechnology, USA. GAPDH was purchased from Proteintech. After washing, membranes were incubated for 2 h with secondary antibody (1:5,000). Signal enhancement was performed using the SignalBoost™ Immunoreaction Enhancer Kit (Merck). Membranes were inserted into clear plastic wraps and Western Blotting Luminol Reagent (Santa Cruz Biotechnology) was added. The signal from the membranes was transferred to the X-ray film that was treated sequentially with a developer and a fixer to visualize the bands. The bands were analysed using ImageJ (Supplementary Fig. S1). RT -qPCR method After treatment, medium was removed, and cells were washed with PBS. Cells were lysed in TRIZOL reagent (Thermo Fisher Scientific). Chloroform was added, and the mixture was vortexed for 30 s, incubated for 5 min, and centrifuged at 13,000 RPM for 15 min at 4 °C. The aqueous phase was collected, mixed with isopropanol, and centrifuged (13,000 RPM, 10 min, 4 °C). Supernatant was discarded and replaced with ethanol to wash the RNA pellet, followed by centrifugation (9,600 RPM, 5 min, 4 °C). Ethanol was removed, and the RNA pellet was dissolved in dH2O. RNA quality was measured spectrophotometrically (260/280 nm and 260/230 nm) using NanoPhotometer Pearl (Implen GmbH, Germany). RNA was diluted to 2 µg in 10 µl of dH2O. Reverse transcription was performed using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) with the following program: 25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min, and 4 °C for 5 min. cDNA was diluted 1:90 for GAPDH and 1:10 for all other genes. A reaction mixture containing 0.5 µl of TaqMan probes (Thermo Fisher Scientific, Table 1) and 5 µl of TaqMan Universal PCR Master Mix (Thermo Fischer Scientific) was combined with 4.5 µl of diluted cDNA. RT-qPCR was performed using the following protocol: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Gene expression data were quantified by the method. Table 1TaqMan probes overviewGene symbolTarget nameRefSeq accession no.Assay ID GAPDH Glyceraldehyde-3-phosphate dehydrogenaseNM_002046Hs99999905_m1 ACAN AggrecanNM_001135Hs00153936_m1 RUNX2 Runt-related transcription factor 2NM_001015051.3Hs01047973_m1 SOX9 SRY-box transcription factor 9NM_000346.3Hs00165814_m1 FGF2 Fibroblast growth factor 2NM_002006.4Hs00266645_m1 BGLAP Bone gamma-carboxyglutamate proteinNM_199173.5Hs01587814_g1 COL10A1 Collagen type X alpha 1 chainNM_000493.3Hs00166657_m1 ADAMTS-5 A disintegrin and metalloproteinase with thrombospondin motifs 5NM_007038.4Hs01095518_m1 MMP-3 Matrix metalloprotease 3NM_002422.4Hs00968305_m1 TaqMan probes overview Fluorescent staining To detect RUNX2 in Saos-2 and SW1353 was performed by immunofluorescence staining using specific antibodies. Cells were seeded on IBIDI at a final concentration of 5 x cell/ml, 200 µl per well. After a 24-hour incubation period with IL-1β in serum-free medium, the substances were added at their final concentration (0.5 µg/ml) in serum-free medium for 4 h. Untreated cells were used as a control. After the incubation period, the cells were washed twice with PBS and fixed in 4% formaldehyde for 30 min. After fixation, the cells were treated with Triton X-100 at a concentration of 0.1% for 30 min to make them permeable. Finally, after washing three times with PBS, the cells were blocked at 37 °C for 2 h using 10% BSA. After washing off the excess BSA, 200 µl of RUNX2 antibody (1:500 dilution; Santa Cruz) was added and left to incubate overnight at 4 °C. After three washes with PBS, the cells were then incubated with 200 µl of PBS containing Alexa Fluor 594 (1:2,000 dilution; Thermo Fisher Scientific) at RT away from light for 1 h. Then Slow Fade Diamond with DAPI was added and the cells were observed under a fluorescent microscope (IX3-CBH Olympus), and pictures were taken with an ORCA digital CMOS camera and evaluated using cellSens Dimension (4.3 Olympus). Quantification of fluorescence signal was done using ImageJ. Statistical analysis Statistical analysis was done in the program GraphPad prism 9. The results were reported as a mean ± standard deviation. The t-test was used to statistically compare enzyme activity, protein production, expression, or viability of cells to the control (C) in experiments without inflammation or to the inflamed control (C + IL) in experiments with IL-1β. Statistical comparison in experiments with IL-1β was also performed through t-tests between C and C + IL to cover the significant differences between untreated cells and their inflammation. Comparison was always done between samples with the same incubation time. Significant differences were determined under a p value of 0.05. Statistical significance was defined as: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Results MTT assay To assess the cytotoxicity of the tested substances, cell viability was evaluated using an MTT assay. Saos-2 and SW1353 cells were incubated with various concentrations (0.125, 0.25, 0.5, and 1 µg/ml) of HAp, β-TCP, GO, and ZnO for 24 h. A significant increase in viability compared to the control was detected in Saos-2 cells that were incubated with 0.125 µg/ml HAp (p < 0.05), 0.25 µg/ml β-TCP (p < 0.05), and both 0.25 and 0.125 µg/ml ZnO (p < 0.05) (Fig. 2a). Viability which exceeded the control with no significant difference was observed in HAp- (0.25 µg/ml), β-TCP- (0.5 and 0.125 µg/ml), GO- (0.5, 0.25, and 0.125 µg/ml), and ZnO-treated cells (1 µg/ml). The remaining viabilities of Saos-2 were below the control level, but the difference was not significant. In contrast, SW1353 cells exhibited a more prominent reduction in viability after exposure to 1 (p < 0 0.01) and 0.5 µg/ml (no significant difference) of HAp, all concentrations of β-TCP (significant only for 1 µg/ml p < 0.05), all concentrations of GO (significance p < 0.05, except 0.125 µg/ml which had no significance), as well as all concentrations of ZnO (significance p < 0.01 except 1 µg/ml with significance p < 0.05) (Fig. 2b). The remaining concentrations of the examined substances did not significantly influence SW1353 viability. Based on these findings, a concentration of 0.5 µg/ml was selected for both cell lines in all subsequent bioactivity experiments. Results of MTT assay in Saos-2 and SW1353 cells treated with various concentrations of HAp, β-TCP, GO, and ZnO after 24 h. a Viability of Saos-2 cells. b Viability of SW1353 cells. Control represents cells without any tested substances (just culture medium). Results are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) Production of pro-COL1, pro-COL2 and MMP-9, mineralisation and ALP activity To evaluate the response of ECM metabolism on HAp, β-TCP, GO, and ZnO, protein levels of pro-COL1, pro-COL-2, and MMP-9 and ALP activity were quantified. The production of pro-COL1, pro-COL2, and MMP-9 was measured using ELISA, while ALP activity was determined spectrophotometrically. Pro-COL1 production and ALP enzyme activity was assessed in Saos-2 cells, while the production of MMP-9 and pro-COL2 was measured in SW1353 cells. ALP activity in Saos-2 substance-treated cells did not reveal any significant deviation compared to control cells for both exposure times (Fig. 3a). After 5 h, ALP activity exceeded the activity of the control after the influence of all the tested substances except the GO-treated cells. After 1 week, only β-TCP and ZnO-treated cells had an activity of ALP higher than the control. After 24 h, pro-COL1 levels produced by substance-treated Saos-2 cells were elevated compared to the control in all cases (Fig. 3b). After 1 week, the production of pro-COL1 in all substance-treated cells did not significantly differ from the control. ALP enzyme activity, pro-COL1 production and mineralization by Saos-2 cells, and pro-COL2 and MMP-9 production by SW1353 cells, after exposure to the tested substances. a ALP activity in Saos-2 cells normalised to total protein. b Pro-COL1 production by Saos-2. c Pro-COL2 production by SW1353 cells normalised to total protein. d MMP-9 production by SW1353 cells. e Mineralisation by Saos-2 cells f Saos-2 cells stained with Alizarin Red, 4x magnification, n = 3. C is a control with cells alone; MA represents control with cells in mineralisation medium; MA + CaCl2 stands for a control with cells, mineralisation medium, and CaCl₂. Images labelled HAp, β-TCP, GO, and ZnO show representative images of Saos-2 cells alone following incubation with the respective studied substances. Results for protein production, ALP activity, and mineralisation are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) Pro-COL2 production by SW1353 cells did not exceed the control values with any treatment after 24 h (Fig. 3c). A significant decrease was observed in HAp (p < 0.001), GO (p < 0.001), and ZnO-treated cells (p < 0.01), respectively. A significant increase only occurred after 1 week in β-TCP-treated cells (p < 0.05). Other substance-treated cells over the same period increased the pro-COL2 production compared to the control with no significant difference. MMP-9 secretion by ZnO-treated SW1353 cells was significantly higher than the control after 24 h (p < 0.05). Other substance-treated cells (HAp, GO, ZnO) were lower than the control at this time point, however no significant difference was observed (Fig. 3d). After 1 week, MMP-9 was upregulated by HAp (p < 0.05), β-TCP (p < 0.01), GO (p < 0.01) and ZnO-treated cells (p < 0.01). The effect of the tested materials on calcium deposition and ECM mineralisation was assessed via Alizarin Red staining. Only CaCl2 was able to significantly increase mineralisation after three weeks of incubation (Fig. 3e and f). None of the tested substances positively affected the mineralisation. On the other hand, ZnO significantly decreased mineralisation (p < 0.01). Western blot method after IL-1β cell treatment The protein levels of key transcription factors and signaling molecules (SOX9, RUNX2, and BMP-2/4) in IL-1β-stimulated cells were assessed using the Western blot method, with representative films shown in Fig. 4g. The corresponding uncropped, original Western blot films of SW1353 and Saos-2 cells are available in Supplementary Figs. S2 and S3, respectively. As the protein ladder is inherently non-luminescent, the target protein bands, including instances where secondary non-specific bands appeared, were identified by cross-referencing and aligning the developed films with the physical molecular weight markers visible on the PVDF membrane. Western blot analysis of RUNX2, SOX9, and BMP-2/4 production. C refers to the control with cells not treated with any tested substances or IL-1β. a SOX9 production by Saos-2 cells. b SOX9 production by SW1353 cells. c RUNX2 production by Saos-2 cells. d RUNX2 production by SW1353 cells. e BMP-2/4 production by Saos-2 cells. f BMP-2/4 production by SW1353 cells. Protein levels were normalised to GAPDH. Results a–f are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). g Representative western blot films of Saos2 and SW1353 cells after 5 and 24 h After 5 h, SOX9 production in Saos-2 cells exposed to the substances did not significantly differ from C + IL (Fig. 4a). At this time point, the production of SOX9 was higher than C + IL in β-TCP, GO, and ZnO-treated cells, while production in HAp-treated cells was lower. After 24 h, SOX9 was increased above C + IL only in HAp-treated cells, while β-TCP, GO, and ZnO-treated cells were below it, however all these result had no significant difference compared to C + IL. After 5 h, the production of SOX9 in HAp- and GO-treated SW1353 cells was higher than C + IL, while β-TCP and ZnO-treated cells had the production of SOX9 that was lower (Fig. 4b), but no significant difference was observed. After 24 h, the production of SOX9 in SW1353 cells was lower than C + IL in HAp- and β-TCP-treated cells, and conversely higher in GO- and ZnO-treated cells, but difference compared to C + IL remained with no significance. RUNX2 production in Saos-2 cells compared to C + IL was not significantly changed with any substance treatment (Fig. 4c). HAp-, β-TCP-, and ZnO-treated cells after 5 h, as well as β-TCP– and ZnO-treated cells after 24 h, produced RUNX2 below C + IL. On the other hand, in GO-treated cells at both incubation times and in HAp-treated cells after 24 h, levels of RUNX2 were higher than in the C + IL group. In SW1353 cells, RUNX2 production after 5-hour incubation was not significantly different from C + IL in all groups (Fig. 4d). HAp-, β-TCP, GO, and ZnO-treated cells after 5 h, as well as GO-treated cells after 24 h, produced RUNX2 below C + IL. On the other hand, levels of RUNX2 were higher than in the C + IL group in HAp- (p < 0.05), β-TCP- and ZnO-treated cells after 24 h. BMP-2/4 production in Saos-2 cells was not significantly affected by any of the studied substances at both incubation times compared to C + IL (Fig. 4e). The levels of BMP-2/4 were higher than C + IL in HAp- and β-TCP-treated cells after 5 h, and in HAp-treated cells after 24 h. In contrast, BMP-2/4 levels were lower than in the C + IL in GO- and ZnO-treated cells after 5 h and in β-TCP, GO, and ZnO-treated cells after 24 h. Similarly, no significant differencewas recorded in SW1353 cells (Fig. 4f). HAp, β-TCP, and ZnO-treated cells after 5 h, as well as HAp and β-TCP-treated cells after 24 h, had BMP-2/4 levels lower than C + IL. However, GO-treated cells at both incubation times and ZnO-treated cells after 24 h produced BMP-2/4 higher than the C + IL. RT-qPCR To evaluate the effect of the tested substances on the transcriptional profile of Saos-2 and SW1353 in an IL-1β-stimulated environment, the relative gene expression of SOX9, RUNX2, COL10A1, BGLAP, MMP-3, ACAN, FGF-2, and ADAMTS-5 was quantified using RT-qPCR. Because BGLAP is a late marker specific to osteoblast differentiation and bone formation, its expression was evaluated exclusively in the osteoblast-like Saos-2 cells. Conversely, ACAN expression was measured solely in the chondrocyte-like SW1353 cells, as it encodes aggrecan, a fundamental and specific component of the cartilage extracellular matrix. SOX9 expression in Saos-2 cells treated with substances exhibited no significant difference from C + IL (Fig. 5a). SOX9 expression in β-TCP-treated cells was higher than C + IL, while HAp, GO, and ZnO-treated cells had SOX9 levels lower. Although COL10A1 expression was lower in ZnO-treated Saos-2 cells, the difference was not statistically significant. In contrast, cells treated with HAp (p < 0.01), β-TCP (p < 0.05), and GO (p < 0.05) exhibited significantly reduced expression compared to C + IL (Fig. 5c). The expression of RUNX2 (Fig. 5f), FGF-2 (Fig. 5k), ADAMTS-5 (Fig. 5m), and MMP-3 (Fig. 5h) in all substance-treated Saos-2 cells was lower than in the C + IL group; this decrease had no significance for RUNX2 and FGF-2, however significant difference was observed for MMP-3 (p < 0.01) and ADAMTS-5 (p < 0.05). Osteocalcin (BGLAP) expression in Saos-2 cells treated with substances was below the expression of C + IL (Fig. 5e). The only significant decrease in BGLAP expression was observed in β-TCP-treated cells (p < 0.05). Results from RT-qPCR analysis of genes in Saos-2 and SW1353 cells treated with HAp, β-TCP, GO, and ZnO, following IL-1β treatment after 4 h. a SOX9 in Saos-2 cells. b SOX9 in SW1353 cells. c COL10A1 in Saos-2 cells. d COL10A1 in SW1353 cells. e BGLAP in Saos-2 cells. f RUNX2 in Saos-2 cells. g RUNX2 in SW1353 cells. h MMP-3 in Saos-2 cells. i MMP-3 in SW1353 cells. j ACAN in SW1353 cells. k FGF-2 in Saos-2 cells. l FGF-2 in SW1353 cells. m ADAMTS-5 in Saos-2 cells. n ADAMTS-5 in SW1353 cells. Expression levels were normalised to GAPDH. Results are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) In SW1353 cells, SOX9 expression did not significantly differ from C + IL (Fig. 5b). SOX9 expression in GO-treated SW1353 cells was lower than in C + IL, while SOX9 expression in the cells incubated with HAp, β-TCP, and ZnO were above the SOX9 levels of C + IL. COL10A1 expression was reduced in all substance-treated cells, with significance p < 0.05 for HAp, β-TCP, and GO, and p < 0.01 for ZnO-treated cells (Fig. 5d). RUNX2 expression compared to C + IL was higher only in SW1353 cells treated with HAp, but no significant difference was observed (Fig. 5g). The rest of the substance-treated SW1353 cells did not reach the expression of C + IL. Only significant decrease of RUNX2 expression was observed in GO-treated cells (p < 0.05). MMP-3 expression in all substance-treated SW1353 cells was significantly lower than C + IL (p < 0.05) (Fig. 5i). FGF-2 expression in SW1353 cells treated with HAp (no significance) and GO (p < 0.05) were below the levels of C + IL (Fig. 5l). The SW1353 cells influenced by the remaining substances (β-TCP and ZnO) had higher expression of FGF-2 compared to C + IL, however the difference was not significant. ADAMTS-5 expression was decreased compared to C + IL in all substance-treated SW1353 cells with significance for HAp (p < 0.05), GO (p < 0.05), and ZnO-treated cells (p < 0.01) (Fig. 5n). β-TCP-treated SW1353 cells exhibited no significant difference in ADAMTS-5 expression compared to C + IL. ACAN expression in substance-treated SW1353 did not exhibit any significant difference compared to C + IL (Fig. 5j). HAp, β-TCP, and GO-treated cells expression of ACAN was lower than C + IL. On the other hand, ZnO-treated cells had insignificantly higher expression levels of ACAN than C + IL. ELISA method To assess the extracellular response to the tested substances, the levels of specific matrix proteins (pro-COL1, pro-COL2) and inflammatory markers (IL-6, IL-8) in the supernatant of IL-1β-stimulated cells were measured via ELISA. Pro-COL1 production by substance-treated Saos-2 cells did not significantly change compared to C + IL for both incubation periods (Fig. 6a). The production of pro-COL1 by β-TCP-, GO-, and ZnO-treated Saos-2 cells was lower than C + IL for both incubation periods. The production of pro-COL1 by HAp-treated Saos-2 cells exceeded the C + IL for both incubation periods. Pro-COL2 production by all substance-treated Saos-2 cells showed no significant difference compared to C + IL (Fig. 6d). The amount of pro-COL2 production by HAp, β-TCP, and GO-treated cells was higher than C + IL after 5 h and by HAp-treated cells after 24 h. The remaining substance-treated Saos-2 cells (β-TCP, GO – 5 h; ZnO both incubation times) did not exceed the production of C + IL. IL-6 production was lower than C + IL at β-TCP (p < 0.05), GO (no significant difference), and ZnO-treated (p < 0.05) Saos-2 cells after 5 h and ZnO-treated Saos-2 cells (no significant difference) after 24 h (Fig. 6g). Other substance-treated Saos-2 cells (HAp – 5 h; HAp, β-TCP, GO – 24 h) produced higher amount of IL-6 than in the C + IL, however the difference was not significant. IL-8 production by substance-treated Saos-2 cells was not significantly different from C + IL (Fig. 6c). The production of IL-8 by HAp-treated Saos-2 cells after 5 h and β-TCP- and GO-treated cells after 24 h was higher than C + IL. The remaining substance-treated Saos-2 cells (β-TCP, GO, ZnO – 5 h; HAp, ZnO – 24 h) did not exceed the production of C + IL. ELISA results. a Production of pro-COL1 by Saos-2 cells. b Production of pro-COL1 by SW1353 cells. c Production of IL-8 by Saos-2 cells. d Production of pro-COL2 by Saos-2 cells. e Production of pro-COL-2 by SW1353 cells. f Production of IL-8 by SW1353 cells. g Production of IL-6 by Saos-2 cells. h Production of IL-6 by SW1353 cells. Protein levels were normalised to total protein. Results are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) There were no significant differences in pro-COL1 production in substance-treated SW1353 cells compared to C + IL, except for lower production in ZnO-treated cells (p < 0.05) after 24 h (Fig. 6b). The only insignificant pro-COL1 production, which was higher than C + IL, was observed for HAp-treated SW1353 cells after both incubation periods. Pro-COL2 production by HAp (no significant difference), β-TCP (no significant difference), GO (p < 0.001), and ZnO-treated (p < 0.01) SW1353 cells after 5 h and β-TCP- (no significant difference) and ZnO-treated (no significant difference) cells after 24 h increased above C + IL (Fig. 6e). The remaining substance-treated SW1353 cells (HAp, GO – 24 h) produced pro-COL2 below the levels of C + IL with no significant difference. IL-6 production by substance-treated SW1353 cells did not exhibit any significant changes compared to C + IL after 5 h (Fig. 6h). At this time point, IL-6 levels increase above the levels of C + IL in HAp, GO, and ZnO-treated cells, but β-TCP-treated SW1353 cells did not reach the levels of the control treated with IL-1β. After 24 h, a decrease in IL-6 production below the level of C + IL was observed in HAp (no significant difference), β-TCP (p < 0.001), GO (p < 0.05), and ZnO-treated (p < 0.05) SW1353 cells. IL-8 production by substance-treated SW1353 cells did not significantly change compared to C + IL for both incubation times (Fig. 6f). After 5 h, all substance-treated SW1353 cells produced IL-8 above the levels of C + IL, but after 24 h production dropped below it. Fluorescent staining To assess the spatial distribution and potential functional state of the RUNX2 transcription factor, the treated Saos-2 and SW1353 cells were analysed using immunofluorescence microscopy. Both Saos-2 and SW1353 cells were stained positively with the specific antibody for RUNX2 (Fig. 7a and b). However, clear differences in cellular distribution were observed among the different treatments. In C + IL Saos-2 cells and Saos-2 cells treated with, HAp, β-TCP, and GO, the localisation of RUNX2 was predominantly nuclear, whereas ZnO-treated Saos-2 cells and untreated controls exhibited cytoplasmic RUNX2 (Fig. 7c). In contrast, SW1353 cells exhibited higher cytoplasmic RUNX2 signals in both controls (C and C + IL) and all substance-treated cells (Fig. 7d). The strongest nuclear RUNX2 signals in Saos-2 were observed in β-TCP-treated cells (88.73% of total RUNX2, p < 0.01). The strongest nuclear RUNX2 signals in SW1353 were detected following GO treatment cells (58.48% of total RUNX2), with no statistically significant difference observed compared to C + IL. The lowest amount of nuclear RUNX2 was observed in both cell lines after ZnO treatment (34.11% in Saos-2, p < 0.001 and 24.97% in SW1353, p < 0.001). Fluorescence microscopy images of Saos-2 and SW1353 cells stained with immunofluorescence-specific antibody for RUNX2 (red colour) and DAPI (blue colour), and relative quantification of RUNX2 distribution in cells. C refers to cells that were not treated with the substances or IL-1β. C + IL refers to cells treated with IL-1β but not with any substances. a Saos-2 cells images. b SW1353 cells images. 40x magnification, n = 3. c Relative quantification of fluorescence in Saos-2 cells showing percentage distribution of RUNX2 between nucleus and cytoplasm. d Relative quantification of fluorescence in SW1353 cells showing percentage distribution of RUNX2 between nucleus and cytoplasm. Results in c and d are presented as mean ± standard deviation, n = 3. Statistical significance: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) Discussion Repairing osteochondral defects remains a significant challenge due to the different regenerative capacities of bone and cartilage. This is further complicated by chronic inflammation in conditions such as osteoarthritis and osteitis [1, 15, 28]. This study evaluated the immunomodulatory and regenerative capacity of HAp, β-TCP, GO, and ZnO on Saos-2 and SW1353 cells under IL-1β-simulated inflammatory conditions [29, 30]. Firstly, we conducted a series of experiments without the IL-1β stimulation, to establish a profile of cell response to substances for the selected parameters. Given the critical role of the inorganic matrix in bone tissue, it was essential to evaluate ALP activity and the mineralisation capacity of Saos-2 [31]. Our results showed that ALP activity remained unaffected; none of the treatments significantly increased or decreased its activity compared to the control. This indicates that without additional osteogenic supplements (e.g. vitamin C, Mg2+), these substances cannot accelerate the synthesis of inorganic ECM [32]. Notably, ZnO treatment appeared to inhibit mineralisation. This inhibition might be linked to the downregulation of sodium-dependent phosphate cotransporters (PiT-1 and PiT-2), restricting the phosphate uptake required for hydroxyapatite formation [33]. The evaluation of the immunomodulatory potential of the tested substances under the inflammatory conditions revealed a complex, cytokine-specific response. Although IL-8 secretion remained unaffected by treatment in both cell lines, SW1353 cells exhibited a delayed, cell-specific reduction in IL-6 in response to β-TCP, GO, and ZnO. This temporal modulation is highly favourable for osteochondral regeneration, as it permits early repair signalling while mitigating the prolonged degradation mediated by IL-6 [34, 35]. This chondrocyte-specific effect suggests targeted intracellular interactions, such as the gradual release of bioactive ions from β-TCP and ZnO, or the ROS scavenging capability of GO, that potentially interfere with downstream transcription factors such as NF-κB [16, 24]. Further investigation is needed to define the regulatory pathways underlying this interaction. Our selected concentration of the substances (0.5 µg/ml) had different effects on the viability of the Saos-2 and SW1353 cell lines. While well-tolerated by Saos-2 cells, it caused a more measurable decline in SW1353 cells treated with GO and ZnO, reducing their viability to approximately above 70%. We define this effect as subtoxic because, although it represents a clear biological burden on the cells, the viability successfully remained above the 70% cytotoxicity limit established by the ISO 10993-5 standard [27]. Maintaining this uniform concentration was a necessary compromise to deliver a robust, comparable bioactive stimulus against inflammatory degradation across all tested groups without causing definitive cytotoxicity. To further elucidate the regulatory mechanisms governing cell functions under inflammatory stress, we analysed the production of BMP-2/4 and expression of FGF-2. These growth factors are equally critical in cartilage and bone regeneration. FGF-2 stimulates the initial cellular expansion at the defect site, while BMP-2 and BMP-4 drive functional maturation and matrix deposition (e.g. COL1, COL2, COL10A1) in both bone and cartilage [36, 37]. Despite the presence of osteoconductive substances, the production of BMP-2/4 remained unaffected by any treatment of both cell lines. The absence of significant BMP-2/4 upregulation partly explains the lack of induction in specific osteogenic and chondrogenic markers, namely the stagnant expression of RUNX2, BGLAP, and production of pro-COL1 in Saos-2 cells, and the non-significant changes in SOX9 and ACAN in SW1353 cells. Concurrently, the lack of this differentiation signal aligns with the observed significant suppression of the hypertrophic marker COL10A1 [38, 39]. FGF-2 expression exhibited substance and cell-specific modulation, with a significant downregulation observed in GO-treated SW1353 cells. Although FGF-2 is traditionally considered a mitogenic and reparative growth factor, it often synergises with IL-1β under inflammatory stress to drive matrix degradation and angiogenesis in adult articular cartilage [40]. Therefore, the targeted suppression of FGF-2 by GO may represent a unique chondroprotective mechanism to prevent inflammatory amplification. ECM homeostasis is fundamental to the structural and functional integrity of bone and cartilage tissues. However, it can be disrupted in inflammation-driven pathologies such as osteoarthritis or osteitis via the upregulation of MMPs and the suppression of ECM synthesis [8, 41, 42]. While HAp alone exhibited a non-significant trend in increase pro-COL1 levels by Saos-2 cells, the remaining substances failed to enhance pro-COL1 production to the levels observed in the C + IL. This observation aligns with the results obtained for BMP-2/4, where only HAp managed to increase the production of this growth factor. GO and ZnO were found to significantly increase the early production of pro-COL2 in SW1353 cells, despite ACAN expression remaining unaffected. This rapid response may be driven by GO-induced TGF-β signalling and zinc-mediated Nrf2 activation, triggering a compensatory antioxidant response [25, 26]. However, this chondro-supportive effect diminished by 24 h, suggesting it is transient or eventually overwhelmed by the sustained inflammatory signalling driven by exogenous IL-1β and the subsequent intercellular response [43]. Importantly, all the tested substances significantly downregulated the expression of the ECM-degrading enzyme MMP-3 across both cell lines. Similarly, ADAMTS-5 expression was significantly reduced by all substances in both cell lines, except for β-TCP in SW1353 cells, where the decrease did not reach statistical significance. These findings align with current models of osteochondral crosstalk between cartilage and bone, which suggest that suppressing ECM-degrading enzymes in both compartments simultaneously is crucial to prevent the diffusion of catabolic signals across the bone-cartilage interface and halt the pathological feed-forward loop [44]. This suppression, alongside reduced IL-6 secretion by SW1353 cells, suggests these substances beneficially disrupt the inflammatory feedback loop [45]. During osteoarthritic progression, chondrocytes often undergo pathological hypertrophy characterized by COL10A1 expression, which alters ECM composition and exacerbates the production of matrix-degrading enzymes [46]. Furthermore, the concurrent promotion of hyaline-like matrix synthesis and robust downregulation of COL10A1 expression confirms that all the tested substances effectively protect the ECM of SW1353 cells from both inflammatory degradation and this undesirable late-stage hypertrophy [47]. An apparent discrepancy was observed regarding the secretion of MMP-9. While the tested substances successfully downregulated the gene expression of the primary ECM-degrading enzymes MMP-3 and ADAMTS-5, following IL-1β treatment, ELISA results revealed a significant upregulation of MMP-9 in SW1353 cells after one week of treatment with substances. Although MMP-9 is generally associated with matrix degradation, its delayed upregulation may reflect a necessary physiological transition from the initial protective phase to a tissue remodelling phase [48]. Unlike MMP-3 and ADAMTS-5, which aggressively cleave intact native structural components like aggrecan, MMP-9 functions primarily as a gelatinase that clears denatured collagens and the provisional matrix [48]. Western blot analysis of Saos-2 cells revealed that only the HAp treatment significantly upregulated the protein levels of SOX9 (a transcription factor involved in early osteochondral progenitor maintenance) above the C + IL group after 24 h [49]. This phenomenon reflects cellular plasticity in mineralised microenvironments, suggesting that HAp helps stabilize the early cellular phenotype of Saos-2 against cytokine attack [50, 51]. For possible cartilage regeneration, GO demonstrated a profound chondroprotective effect by significantly downregulating the gene expression of both RUNX2 and FGF-2. Since RUNX2 drives terminal differentiation and undesirable cartilage calcification, the ability of GO to suppress its expression while simultaneously boosting early pro-COL2 production preserves the functional chondrogenic phenotype against inflammatory degeneration, likely via canonical TGF-β activation [25, 52]. RT-qPCR analysis of RUNX2 further elucidated ZnO-impaired bioactivity, while RT-qPCR indicated that RUNX2 mRNA levels in Saos-2 cells treated with HAp, β-TCP, GO, and ZnO tended to be lower than in the C + IL. However, this transcriptional suppression alone does not explain the unique inhibitory effect of ZnO. Immunofluorescence staining revealed a functional distinction in Saos-2 cells treated with HAp, β-TCP and GO, in which RUNX2 was predominantly nuclear. This nuclear localisation preserved its potential for transcriptional activity despite the lower expression levels observed. In contrast, ZnO-treated cells exhibited significant cytoplasmic retention of RUNX2. This mislocalization implies functional inactivation of the RUNX2, which aligns with the results of our mineralisation assays, where only ZnO significantly inhibited mineralisation [53]. Therefore, it is likely that the primary mechanism by which ZnO actively suppresses osteogenic functions is cytoplasmic trapping rather than reduced gene expression per se. This sets ZnO apart from the biocompatible properties of HAp, GO and β-TCP. While this study provides valuable insights into the immunomodulatory potential of the tested substances, several limitations must be acknowledged. Firstly, the experiments involving substance exposure and IL-1β stimulation were conducted under serum-free conditions. This design was deliberately chosen to isolate the specific cellular responses to IL-1β and to prevent undefined serum proteins from forming a protein corona around the particles, which could alter their bioactivity. Although the substance incubation times were kept relatively short (4, 5, or 24 h) to minimize the cellular stress associated with serum starvation, the temporary absence of essential growth factors may still limit the direct translation of these findings to a highly complex, protein-rich in vivo environment. Secondly, the study utilized human immortalized Saos-2 and SW1353 cell lines, which ensure robust and reproducible baseline comparisons for screening. Although, the cell lines possess different metabolic and phenotypic profiles compared to primary human osteoblasts and chondrocytes, the primary cells reveal higher biological variability [54, 55]. Finally, the immunofluorescence analysis of RUNX2 distribution was evaluated at a single time point of 4 h. While this successfully captured the initial intracellular translocation, it does not account for the dynamic, time-dependent spatial shifts of RUNX2 that may occur during prolonged inflammatory exposure. Conclusions This study demonstrated that while subtoxic concentrations of HAp, β-TCP, GO, and ZnO did not induce ALP activity, mineralisation, or BMP-2/4 production, they act as effective protective agents against the inflammatory degradation of ECM. All tested substances downregulated the expression of the ECM enzymes MMP-3 and ADAMTS-5, in both Saos-2 and SW1353 cells, while suppressing the expression of the late-stage hypertrophy marker COL10A1. Specific responses were observed in the maintenance of cellular phenotypes under inflammatory conditions. HAp demonstrated the capacity to sustain the early phenotype in Saos-2 cells by significantly upregulating SOX9 protein levels. In SW1353 cells, GO exhibited a distinct chondroprotective effect by downregulating RUNX2 and FGF-2 gene expression. This prevented inflammatory amplification and undesirable cartilage calcification, while simultaneously boosting early pro-COL2 production. The study further elucidates the mechanism behind the impaired bioactivity of ZnO. Although all treatments resulted in lower RUNX2 mRNA levels, specifically ZnO-treated cells exhibited significant cytoplasmic trapping of the RUNX2 protein. Overall, these findings highlight the potential of utilizing these bioactive compounds. By actively counteracting inflammatory ECM degradation, they offer a promising strategy for enhancing osteochondral regeneration in chronic inflammatory environments, such as osteoarthritis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 1097.3 kb) Acknowledgements The authors are grateful to Ben Watson-Jones for English proofreading. Author contributions R.N. - methodology, analysis, interpretation of data and preparing the figures, writting he draft I.R. - drafting the work, reviewing J.F. - conceptualization, drafting the wotk, methodology, interpretation of data All authors contributed on writiting and editing of final version of the manuscript. Funding This work was supported by the Grant Agency of the Czech Republic 21–45449 L and Internal Grant Agency of the Faculty of Medicine, Palacky University Olomouc (IGA_LF_2026_009) and by the National Science Centre, Poland 2020/39/I/ST5/00569 (OPUS-LAP). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1 (DOCX 1097.3 kb) Data Availability Statement No datasets were generated or analysed during the current study.